Template:COVID Remdesivir
Remdesivir
- For 5 days or until the time of hospital discharge, whichever comes first.
- Indication[1]
- SpO2≤94% on ambient air (at sea level) or requiring supplemental oxygen via low flow device
- There is insufficient data to recommend for or against use in patients using high flow oxygen, mechanical ventilation or ECMO (NIH COVID-19 Guidelines).
- Contraindications[2]
- Alanine transaminase or aspartate transaminase >5 times the upper limit of normal
- Creatinine clearance of <30 mL/minute
- Can be considered in patients with calculated creatinine clearance of <30 mL/minute and in patients receiving hemodialysis if the benefits outweigh the risk (limited data).
- At this time, there are no recommended dose adjustments for this patient population.
- Pediatric patients 3.5kg to 12 years of age; should not be given if ALT is >10 times normal.[3]
